Table 1: Patient demographics and clinical data.

Age (years), median (IQR) 11.2 (10-15.3)
Sex (% Male) 66.7
Asthma, n (%)
    Lung functiona, n (% of asthma patients)
      FEV1%, median of predicted value (IQR)
      MEF25-75 (l/s), median (IQR)
      Median FeNO (ppb), median (IQR)
    Treatment, n (% of asthma patients)
      CS + BD + LA
      CS + BD
      CS
      BD
      No treatment
      Data not available 		20 (95.2)
8 (40)
93 (85.3-125)
68.5 (64.8-99.8)
18.5 (7.8-27.1)

3 (15)
13 (65)
1 (5)
1 (5)
1 (5)
2 (10%)
Allergic rhinitis, n (%) 7 (33.3)
Atopic dermatitis, n (%) 3 (14.3)
Sensitization to allergens, n/tested (%)
    D. pteronyssinus/D. farinae
    Alternaria
    Cat dander
    Dog dander
    Birch pollen
Grass pollen
21/21 (100)
1/15 (6.7)
11/19 (57.9)
8/15 (53.3)
4/18 (22.2)
8/18 (44.4)

aLung functions performed within 1 month before onset of cluster regimen.
Note: BD: bronchodilator; CS: corticosteroid; FeNO: fractional exhaled nitric oxide; FEV1: forced expiratory volume in 1 second; IQR: interquartile range; LA: leukotriene antagonist; MEF25/75: mid expiratory flow between 25% and 75% of expired volume.